Ocugen (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines, has closed on its previously announced underwritten public offering. The offering was comprised of 30,434,783 shares of its common stock, with each share sold at $1.15 per share. The company is anticipated to receive an estimated $35 million in gross proceeds, before standard deductions and expenses are made. Ocugen plans to use the funds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/XgLie
About Ocugen Inc.
Ocugen is a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company is making an impact on patient’s lives through courageous innovation, forging new scientific paths that harness its unique intellectual and human capital. Ocugen’s breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and the company is advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
To learn more about the company, visit www.Ocugen.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN